Diabetes is a disease of high blood sugar. Diabetic patients also can experience extremely low blood sugar, or hypoglycemia, after fasting, exercising or too large a dose of insulin. If untreated, severe hypoglycemia can lead to coma or even death.

Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced it has closed on $1.8M in Series A financing to support the launch of its new microbiome platform technology.  

Celdara Medical, LLC today announced that it has successfully concluded negotiations with Celyad SA (Euronext Brussels and Paris, and NASDAQ:CYAD) related to their ongoing partnership for discovery and development of CAR T cell therapies.

Virtici announced today that it has received a three-year, $3.5 million award from the National Institutes of Health (NIH) to support an Institutional Development Award (IDeA) Center of Biomedical Research Excellence.

The Maryland Technology Development Corporation (TEDCO) announced today that six companies, including Virtici spinout Rise Therapeutics, received a total of $800,000 in seed funding. 

Virtici, LLC announced today the spin-out of a new drug development company, Rise Therapeutics, which is focused on developing microbiome-based, immunological therapies. To form the spin-out, Rise obtained key microbiome-related intellectual property and technologies incubated at Virtici to support the development of first-in-class, orally-delivered, biological medicines.